(MENAFN- EQS Group)
DGAP-Media / 14.01.2022 / 14:45
HAEMATO distributes PCR point-of-care devices for effective containment of corona pandemic
Schönefeld, 13th January 2022 - With the current omicron wave, laboratories in Germany are facing a sharp increase in PCR testing. The evaluation capacities are pushing increasingly towards their limits, especially with regards to the new quarantine regulations.
HAEMATO PHARM GmbH ('HAEMATO'), a 100% subsidiary of HAEMATO AG (ISIN: DE000289VV1), has now added a high-end PCR point-of-care device to its portfolio. This device can perform a reliable RT (real-time)-PCR analysis within 45 minutes. HAEMATO already supplies numerous pharmacies, clinics and laboratories, thus reducing the workload of these facilities.
RT-PCR testing is the so-called gold standard among corona tests. The polymerase chain reaction (PCR) can be used to reliably detect pathogens in a sample from the respiratory tract mucous membranes. As the RT-PCR devices offered by HAEMATO can be used on site (point-of-care), the long way from taking the sample to the analysing laboratory is saved. The entire process is thus considerably shortened and thus accelerated.
'In addition to our day-to-day business of supplying medicines, we are currently working non-stop to supply pharmacies, clinics, laboratories and public institutions with RT-PCR devices, rapid antigen tests and FFP2 masks,' says Patrick Brenske, CEO of HAEMATO AG. Attila Strauss, Managing Director of HAEMATO PHARM GmbH added: 'We recognised the potential overload in healthcare at an early stage and with the addition of the PCR Point-of-Care devices to our product portfolio, we are now in a position to make an important contribution to the battle against the Corona pandemic.'
The PCR Point-of-Care devices as well as standard rapid antigen tests and FFP2 masks are available for order and immediate delivery via the website .
HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on trading in high-priced special pharmaceuticals (with a therapeutic focus on oncology, HIV, rheumatology, and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of 'Lifestyle & Aesthetics'. HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information can be found at .
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
End of Media Release
Issuer: HAEMATO AG
Key word(s): Enterprise
14.01.2022 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
| Language: || English |
| Company: || HAEMATO AG |
| || Lilienthalstraße 5c |
| || 12529 Schönefeld |
| || Germany |
| Phone: || +49 (0)30 897 30 86 70 |
| Fax: || +49 (0)30 897 30 86 79 |
| E-mail: || |
| Internet: || |
| ISIN: || DE000A289VV1 |
| WKN: || A289VV |
| Listed: || Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange |
| EQS News ID: || 1269035 |
Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.